LeMaitre Vascular, Inc. $LMAT Shares Sold by Summit Creek Advisors LLC

Summit Creek Advisors LLC reduced its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 7.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 155,903 shares of the medical instruments supplier’s stock after selling 12,481 shares during the period. LeMaitre Vascular comprises 2.0% of Summit Creek Advisors LLC’s investment portfolio, making the stock its 27th largest holding. Summit Creek Advisors LLC owned approximately 0.69% of LeMaitre Vascular worth $13,643,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust grew its stake in shares of LeMaitre Vascular by 1,913.3% in the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 287 shares in the last quarter. Geneos Wealth Management Inc. boosted its holdings in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the period. EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the 2nd quarter worth $47,000. Laurel Wealth Advisors LLC grew its stake in LeMaitre Vascular by 8,205.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,495 shares of the medical instruments supplier’s stock worth $124,000 after purchasing an additional 1,477 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in LeMaitre Vascular by 398.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,736 shares of the medical instruments supplier’s stock worth $144,000 after purchasing an additional 1,388 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on LMAT shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research note on Monday, November 10th. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, Roth Capital reiterated a “buy” rating and set a $108.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.20.

LeMaitre Vascular Stock Down 0.0%

Shares of NASDAQ:LMAT opened at $85.00 on Monday. The company has a market capitalization of $1.93 billion, a PE ratio of 36.64, a P/E/G ratio of 1.89 and a beta of 0.68. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $105.55. The firm has a 50 day simple moving average of $84.76 and a 200-day simple moving average of $87.33.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The firm had revenue of $61.05 million for the quarter, compared to the consensus estimate of $62.18 million. During the same period last year, the firm posted $0.49 EPS. The company’s revenue was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 4th. Stockholders of record on Thursday, November 20th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, November 20th. LeMaitre Vascular’s payout ratio is presently 34.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.